Skip to main content

Market Overview

The Best BioPharma Plays Amid Uncertainty From Trump Comments

The Best BioPharma Plays Amid Uncertainty From Trump Comments

Pharma sector was hit following the comments made by President-elect Donald Trump who alluded to potential tightening of industry regulation.

At his first press conference since being elected, Trump said the pharmaceutical industry is “getting away with murder” in terms of product pricing. He asserted that “we need new bidding procedures.”

Leerink said lack of specifics on government negotiation of drug prices confirms a speculated overhang and reversed pharma/biotech rally.

“Without specifics on the kind of changes his administration or the Republican Congress may be planning, we expect this uncertainty to persist until we at least get some specifics,” analyst Seamus Fernandez wrote in a note.


Fernandez recommends companies such as Bristol-Myers Squibb Co (NYSE: BMY) and AstraZeneca plc (ADR) (NYSE: AZN), which have greater and more durable pricing power and are focusing on categories like oncology and rare disease.

“We continue to believe that innovation, particularly innovation for deadly diseases like cancer, will continue to be rewarded,” Fernandez highlighted.

Further, the analyst expects more companies to come clear on average net price increases to shift the debate away from list price increases.

At last check, Direxion Daily S&P Biotech Bear 3X Shares (NYSE: LABD) had fallen as much as 6.6 percent. Bristol-Myers shares were down 0.63 percent to $56.44, while ADRs of AstraZeneca marginally gained 0.28 percent to $28.26.

Image Credit: Derived from "Trump (12/8)" by Max Goldberg from USA - Trump (12/8), CC BY 2.0, via Wikimedia Commons

Latest Ratings for AZN

Apr 2021Argus ResearchDowngradesBuyHold
Mar 2021JefferiesUpgradesHoldBuy
Mar 2021SVB LeerinkMaintainsOutperform

View More Analyst Ratings for AZN
View the Latest Analyst Ratings


Related Articles (AZN + BMY)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Health Care Politics Events Analyst Ratings Movers Best of Benzinga

Latest Ratings

SAMEvercore ISI GroupMaintains1,500.0
SEAutonomous ResearchInitiates Coverage On378.0
ALHCMorgan StanleyInitiates Coverage On36.0
ALHCRaymond JamesInitiates Coverage On30.0
HAEMorgan StanleyDowngrades83.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at